PARP11-driven MARylation of MHC-I in cancer cells causes immune evasion and therapy resistance
Background
The tumor microenvironment (TME) often fosters immunosuppression, allowing cancer cells to evade immune surveillance and resist therapies. Mono-ADP-ribosylation (MARylation), a post-translational modification, is an emerging regulator of this anti-cancer immunity. Specifically, the enzyme PARP11 has been implicated in modulating cytotoxic T lymphocytes (CTLs) and regulatory T cells (Tregs) within tumors. Understanding how cancer cells intrinsically drive immunosuppression, particularly through mechanisms like MARylation, is crucial for overcoming therapeutic resistance and improving patient outcomes in aggressive cancers like pancreatic ductal adenocarcinoma (PDAC).
Study Design
Researchers investigated the role of PARP11 in cancer cells. They induced PARP11 expression in cancer cells using stimuli such as adenosine, epinephrine, or glucagon-like peptide-1 (GLP1). They then performed genetic ablation of PARP11 and pharmacologic inhibition of PARP11 in pancreatic ductal adenocarcinoma (PDAC) cells and a mouse melanoma model. Key endpoints included MHC-I levels, susceptibility to CTL killing, tumor growth, and resistance to chemotherapy and targeted RAS inhibitors. They also assessed the impact on hyperprogressive disease in immune checkpoint inhibitor (ICB)-treated mice.
Results
Stimuli like adenosine, epinephrine, or GLP1 consistently induced PARP11 in cancer cells. This upregulation led to PARP11-mediated MARylation, ubiquitination, and accelerated degradation of MHC-I via the autophagy-lysosomal pathway. This mechanism protected cancer cells from killing by specific CTLs and stimulated tumor growth and progression. Genetic ablation of PARP11 attenuated MHC-I MARylation, ubiquitination, and its interaction with autophagy receptors. Pharmacologic inhibition of PARP11 in PDAC cells:
restored their
MHC-Ilevels, sensitized them to killing byCTLs, inhibited tumor growth, and impeded their initial resistance to chemotherapy and acquired resistance to targeted therapy withRAS inhibitors. Moreover,PARP11inhibition prevented hyperprogressive disease in a mouse melanoma model treated withimmune checkpoint inhibitors (ICBs), suggestingPARP11is a major therapeutically actionable driver of immunosuppression.
Key Findings
- Adenosine, epinephrine, or GLP1 induce PARP11 in cancer cells.
- PARP11 drives MARylation and ubiquitination, leading to MHC-I degradation via the autophagy-lysosomal pathway.
- PARP11 upregulation protects cancer cells from CTL killing and promotes tumor growth.
- Pharmacologic PARP11 inhibition restores MHC-I, sensitizes cancer cells to CTLs, and inhibits tumor growth.
- PARP11 inhibition impedes resistance to chemotherapy and RAS inhibitors, and prevents hyperprogressive disease with ICBs.
Why It Matters
This study identifies PARP11 as a critical, therapeutically actionable driver of immunosuppression and therapy resistance in cancer. Targeting PARP11 could offer a novel strategy to overcome resistance to conventional chemotherapy, targeted therapies like RAS inhibitors, and even enhance the efficacy of immune checkpoint inhibitors (ICBs). For clinicians and biohackers, this suggests a potential pathway to sensitize tumors to existing treatments by modulating the tumor's intrinsic immune evasion mechanisms. While currently preclinical, these findings lay the groundwork for developing PARP11 inhibitors as adjuncts to current cancer therapies, potentially improving responses in patients with aggressive or resistant cancers.
parp11
marylation
mhc-i
immunosuppression
cancer
immune-evasion